Did This Company Make Narcan for COVID?

Narcan nasal spray has saved thousands of lives and made millions for investors. Jason Williams just got a tip about a company that may have developed the same type of thing to treat COVID. Narcan nasal spray has saved thousands of lives and made millions for investors. Jason Williams just got a tip about a company that may have developed the same type of thing to treat COVID. [Wealth Daily logo] Did This Company Make Narcan for COVID? [Jason Williams Photo] By [Jason Williams]( Written Dec 13, 2021 Editor's note: I just wanted to make sure you had a chance to check out the incredible income opportunity I sent you on Friday. There are still a couple of days left to get involved and I don't want you to miss out on the massive payout coming later this week on December 15. [Get access today,]( before it's too late. Best. — JW --------------------------------------------------------------- On July 23, 2014, a major step forward in medical treatment was made. And over the next three years, the company responsible for taking that step returned nearly 1,000% for its investors. And right now, at this exact moment in time, we’re about to witness another company take a similar step that’s all but guaranteed to return just as much — maybe even more — to investors who get in now. Putting the Power in Your Hands The company I led off with was, at the time, known as Lightlake Therapeutics. Shortly after taking that first step, it changed its name to Opiant Pharmaceuticals to better fit its focus. And that focus was treating opioid overdoses and saving lives. The company had developed a nasal spray it called Narcan that could revive overdose victims. And it filed its first investigational NDA with the Food and Drug Administration on that fateful day back in 2014. By 2017, Narcan had gotten full approval and was heading to the bags of every EMT in the nation. But that’s not all. Because of the ease of use, anyone can save an overdose victim with Narcan. So it also went out to tens of thousands of regular people like you and me. And we’ve saved over 27,000 lives so far. That’s just us. That doesn’t count all the people revived by EMTs or later at a hospital. Opiant literally put the power to save a life into the hands of everyday people. And thanks to that brilliant design, it also put millions into the bank accounts of early investors. Between applying for that first NDA in 2014 and getting full approval in 2017, Opiant’s stock soared over 870%: [OPNT Narcan Gain] The #1 Strategy for Biotech Stocks? It’s no secret that biotech is the most exciting investment arena there is. There’s never a shortage of demand for new treatments for the world’s worst diseases, like cancer, Alzheimer’s, and arthritis. And with my new trading system, “Project Greenlight,” you’ll always know with up to 95% confidence which of those new medicines will be approved by the FDA and which won’t... This could set investors up to make six figures or more in biotech profits. And right now, there's a tiny biotech firm trading for pennies on the dollar with a medicine that’s on the brink of FDA approval... [Learn more about this unique opportunity today.]( That scored every early investor an $8,712 profit for every $1,000 they’d invested. That means a respectable $10,000 stake would have been worth $97,120 within just three short years. Almost a hundred thousand dollars of pure profit! That’s the kind of gain investors get when they help fund a company that’s about to change the world. And that’s the kind of gain I’m expecting early investors in another similar small medical company will take home when the world sees what they’ve helped to create. Shots Shots Shots Shots! If there’s one thing we’re getting awfully familiar with, it’s different terms for vaccinations. Shots, jabs, pokes, etc. They’ve all got one thing in common. They’re words used to describe something uncomfortable — a needle getting jammed into your arm. There’s a reason not everyone in the world has tattoos. First, not everyone appreciates them. And second, a lot of the people who think they’re cool just aren’t excited about having a needle stuck into their flesh for several hours straight. Needles hurt. Unfortunately, they’re the only way to get a tattoo. And even more unfortunately, they're also the only way to get some of our most valuable medicine. And you might be surprised to learn that dislike of needles (sometimes a downright fear of them) actually keeps people from getting vaccines that could save their lives. So a company that could produce a way for us to get protected against future infection without getting stabbed or jabbed or poked with a needle… That company could change the world… and make its investors rich in the process. There’s Got to Be Something Better Right now, like it or not, the only vaccine anyone’s really interested in talking about is the COVID one. It’s a hot-button issue, for sure. But it’s a vaccine nonetheless. And it gets delivered by the traditional method. And that’s actually keeping some people from getting it. It also means everyone who administers it has to be trained and certified to stab you with a drug-filled needle. But what if there were something to treat COVID that was like the opioid overdose treatment Narcan? What if there was a COVID spray? That would be incredible! Parents could treat their kids. We could send packages to remote locations without access to trained nurses and they could give themselves the treatment. No overloading the medical system. No spreading the disease when you go out to seek treatment. The company that made that happen would certainly make a pretty penny in the process… just like Opiant Pharma did with its Narcan spray. Well, my friend, such a spray does exist. And I’m convinced the company behind it could make even more than the makers of Narcan did. Because this spray can kill COVID right now. But if the company can make one spray that kills one virus, it can probably make more. We could see a day when we never need to inject medicine ever again. All of our treatments could be delivered through sprays like this. Are you starting to see why it could be even more profitable than Narcan? Are you starting to see the implications? Enter the COVID Killer I hope so. Because after a lot of begging on my part, I convinced my colleague Keith Kohl, the guy who actually tipped me off to this company, to let me share his research with you too. I don’t have enough space to include it here with my article, but I’ll attach it as [a report]( you can read at your leisure. Just don’t be too leisurely about it. People are on the lookout for breakthrough companies like this. It’s only a matter of time before word gets out and the Redditers and Robinhooders of the world start to drive the price up like a rocket ship. I want you to get in BEFORE that happens so you can take home the lion’s share of the profits. So make sure you [give Keith’s report a read]( TODAY. You’ll get all the details on the company and all the information you need to get an early stake in its stock. And I’ll be back later this week with some more insights into the future of the financial markets. To your wealth, [jason-williams-signature-transparent] Jason Williams [[follow basic] @TheReal_JayDubs]( [[follow basic]The Wealth Advisory on Youtube]( [[follow basic]The Wealth Advisory on Facebook]( After graduating Cum Laude in finance and economics, Jason designed and analyzed complex projects for the U.S. Army. He made the jump to the private sector as an investment banking analyst at Morgan Stanley, where he eventually led his own team responsible for billions of dollars in daily trading. Jason left Wall Street to found his own investment office and now shares the strategies he used and the network he built with you. Jason is the founder of [Main Street Ventures](, a pre-IPO investment newsletter, and co-authors [The Wealth Advisory]( income stock newsletter. He also contributes regularly to [Wealth Daily](. To learn more about Jason, [click here](. Browse Our Archives [Italy Goes After Amazon and These Investors Get Paid]( [There's Plastic in Your Tap Water]( [Elon Musk Absolutely Hates This Tech]( [What's the Deal With the Metaverse?]( [The Crisis Nobody's Talking About]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here]( and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add newsletter@wealthdaily.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. Wealth Daily, Copyright © 2021, Angel Publishing LLC. All rights reserved. 3 E Read Street, Baltimore, MD 21202. Your privacy is important to us – we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment advice. Read our [Details and Disclosures.]( ---------------------------------------------------------------